Ghent-based 4Tissue, an innovation-led research and clinical development organisation, has secured an additional €1.5M in funding.
The funding round was secured through a combination of €1M equity investments from strategic investors and grants.
The Belgian company will use the funds to further develop its bioresorbable hydrogel technology, which has the potential to significantly improve breast reconstruction and other tissue regeneration applications.
Additionally, the company will use the capital to prepare for the first clinical studies, including the recruitment of expertise in regulatory affairs and quality control.
Besides funding, 4Tissue welcomes Dr. Katleen Verleysen as the independent chair of the board.
Dr. Katleen Verleysen, currently CEO of miDiagnostics, has held leadership and board positions in several biotech companies across both the US and Europe, where she played a crucial role in securing essential funding and providing strategic direction.
In her new role at 4Tissue, she will guide the company through further funding rounds and strategic growth, to bring the hydrogel technology to patients.
“4Tissue is on the verge of revolutionising breast reconstruction after a breast cancer treatment and regenerative medicine, and I am excited to contribute to this transformation,” says Dr. Katleen Verleysen. “It’s not just a technical breakthrough—it’s a solution that can drastically improve the lives of women recovering from breast cancer, a disease that affects millions worldwide.”
4Tissue: Redefining tissue reconstruction, regeneration, and anti-aging
4Tissue is a biotech company founded through a collaboration between Prof. Phillip Blondeel (a global leader in plastic and reconstructive surgery) and Prof. Dr. Sandra Van Vlierberghe (an expert in polymer chemistry).
The company is a spin-off from Ghent University (UGent), Ghent University Hospital (UZGent), and the Vrije Universiteit Brussel (VUB).
Other founders include Dr. An Van Den Bulcke (COO), Dr. Lana Van Damme, MD (CSO), and Bernard Depypere, MD.
The company develops natural and minimally invasive treatments for tissue reconstruction and regeneration, with applications in different medical fields.
This technology offers a less invasive and simpler approach to breast reconstruction than traditional methods, making it more effective than lipofilling or fat grafting.
CEO Dr. Benoit Moreaux emphasises the strategic importance of her appointment says, “Katleen’s deep knowledge and strategic vision within the life sciences sector make her a valuable addition to our board. Her experience in leading companies through successful funding rounds and building strategic partnerships perfectly aligns with our ambitions to redefine the future of breast reconstruction and tissue regeneration.”
01
Upstream Festival is back for its sixth edition! 4 solid reasons to mark your calendar